Antihypertensives for Kidney Protection
For kidney protection in hypertensive patients, use ACE inhibitors or ARBs as first-line therapy, particularly when albuminuria is present, and add SGLT2 inhibitors regardless of diabetes status if eGFR ≥20 ml/min/1.73 m².
Primary Recommendations by Clinical Context
Patients with Diabetes and CKD
The most recent consensus guidelines 1 establish a clear hierarchy:
- RAS inhibitors (ACE inhibitors or ARBs) at maximum tolerated doses are first-line when hypertension is present
- SGLT2 inhibitors should be initiated if eGFR ≥20 and continued until dialysis or transplant - these provide kidney protection independent of glucose-lowering effects
- Nonsteroidal mineralocorticoid receptor antagonists (finerenone) should be added if albumin-to-creatinine ratio ≥30 mg/g with normal potassium
Patients with Non-Diabetic CKD
ACE inhibitors or ARBs remain the cornerstone for renal protection 2. These agents provide nephroprotection through multiple mechanisms beyond blood pressure reduction:
- Reduction of intraglomerular pressure
- Decreased proteinuria (a direct nephrotoxin)
- Protection of glomerular endothelium and podocytes 3
Blood Pressure Targets
Target BP <130/80 mmHg in all patients with CKD 2, 4. This is more aggressive than the 140/90 mmHg target for uncomplicated hypertension.
Combination Therapy Strategy
Most patients require multiple agents 2, 5:
- Start with ACE inhibitor or ARB (maximum tolerated dose)
- Add diuretic (thiazide-type preferred) as second agent
- Add dihydropyridine calcium channel blocker if additional BP lowering needed
- Consider beta-blocker in patients with high sympathetic drive (elevated pulse rate) 5
Critical Distinction on Calcium Channel Blockers
When albuminuria is present, dihydropyridine calcium channel blockers or diuretics should be added to RAS inhibitors rather than used as monotherapy 1. Non-dihydropyridine calcium channel blockers may have different intrarenal effects 6.
Mechanism-Based Rationale
RAS inhibitors provide nephroprotection through effects independent of systemic blood pressure reduction 4, 7:
- Selective reduction of efferent arteriolar tone
- Decreased intraglomerular capillary pressure
- Antiproteinuric effects beyond BP lowering
- Reduction of intrarenal angiotensin II accumulation 3
This is why RAS inhibitors are preferred over other antihypertensives even when BP control is equivalent - they address intrarenal mechanisms of progressive damage 7, 6.
Common Pitfalls to Avoid
- Do not use ACE inhibitors and ARBs together - combination therapy increases adverse events without additional benefit
- Monitor potassium and creatinine after initiating RAS inhibitors; accept up to 30% creatinine increase if stable
- Do not discontinue RAS inhibitors prematurely for modest creatinine elevations - the long-term renal benefit outweighs short-term GFR reduction
- Achieve maximum tolerated doses of RAS inhibitors before adding other agents for proteinuria reduction 1
Newer Evidence Integration
The 2022 ADA/KDIGO consensus 1 represents the most authoritative current guidance, incorporating SGLT2 inhibitors and nonsteroidal MRAs into the treatment algorithm - this is a paradigm shift from older guidelines 2 that focused exclusively on RAS inhibition. The addition of these agents provides additive nephroprotection when layered onto RAS inhibitor therapy.